Buyouts and growth. Expect LBO modelling, a paper LBO under time pressure, deal/commercial judgement, and "walk me through an investment you’d make".
A sample of the Private Equity bank: the first 3 questions of every topic, with the model answers. 282 questions in total.
32 questions in this topic
For most deals, EBITDA growth (revenue + margin) and debt paydown do the heavy lifting; multiple expansion is a bonus you shouldn't underwrite. Great sponsors underwrite operational improvement, not financial engineering. Be ready to say how leverage magnifies each of these on a smaller equity base.
Entry EV = 10 × 50 = $500m; debt 5 × 50 = $250m; sponsor equity = $250m. Over 5 years you generate cash and pay down a chunk of the $250m debt, say ~$120m, leaving ~$130m. Exit EV = 10 × 75 = $750m; exit equity = 750 − 130 = $620m. MOIC ≈ 620 / 250 ≈ 2.5x → ~20% IRR. Growth and paydown did the work; multiple was flat.
More debt shrinks the equity cheque, so the same absolute value creation sits on a smaller base, magnifying IRR/MOIC, and interest is tax-deductible. But it cuts both ways: higher fixed interest and amortisation reduce the cash cushion, raise default risk, and make the equity the first-loss piece. Sponsors lever to what the cash flows can safely service, not to the maximum.
29 more questions on LBO, with model answers, inside.
36 questions in this topic
~20%. Rule of thumb: 2x in ~3.5 to 4 years ≈ ~20%; 2x in 5 years ≈ ~15%; 3x in 5 years ≈ ~25%. 2.5x over 5 years lands around 20%. Know the common MOIC↔IRR pairs cold: 2x/5y≈15%, 2.5x/5y≈20%, 3x/5y≈25%.
~25% (3^(1/5) − 1 ≈ 0.245). Practise the mental approximation: MOIC^(1/years) − 1.
It lifts IRR meaningfully because cash back sooner is worth more (time value), and it locks in part of your return regardless of the eventual exit, de-risking the deal. MOIC is roughly unchanged (you still collect the same total dollars), but pulling cash forward raises the IRR. The trade-off is a more levered, more fragile company.
33 more questions on Returns, with model answers, inside.
35 questions in this topic
Structure it: market (size, growth, competition), business quality (retention/churn, gross margin, unit economics, moat), financials (growth, cash conversion, existing leverage capacity), the deal (entry multiple, sources & uses, downside), and the value-creation plan and exit. Then take a clear view with the 2 to 3 factors that most drive it. Recurring revenue + high retention + pricing power make SaaS attractive to sponsors, but only at the right entry price.
Commercial (market growth, competitive position, customer concentration, pricing), financial (quality of earnings, working capital, capex, one-offs), operational (management, systems, scalability), legal/regulatory, and the downside case. Tie diligence to the thesis: what has to be true for this to work, and what would break it.
Customer concentration, structural/secular decline, cyclicality that can't service the debt, thin or deteriorating margins, aggressive accounting or poor quality of earnings, high capex/working-capital intensity, weak or misaligned management, and no clear exit. Tie each to the thesis: what has to be true, and what would break it.
32 more questions on Commercial, with model answers, inside.
14 questions in this topic
Lead with the recommendation and the 2 to 3 reasons. Then: business & market, why it's a good (or bad) asset, the numbers (entry, base/downside returns, leverage), key risks and mitigants, the value-creation plan, and the exit. Finish by restating the call. Have a view, sitting on the fence is the failure mode.
~5 min: read the ask, size the market and the business quality. ~15 min: the numbers, entry multiple, a simple sources & uses, base and downside returns, leverage the cash flows can carry. ~5 min: risks and mitigants, the value-creation plan and the exit. ~5 min: structure a clear recommendation, answer first, then two or three reasons and the key risk. Have a view; fence-sitting is the failure mode.
Sponsors underwrite to the downside: can the business service its debt and avoid a zero if growth stalls, a customer leaves, or the multiple compresses? Show the levers most exposed (leverage, cyclicality, concentration), quantify the hit to EBITDA and returns, and identify covenants/headroom. Protecting the equity from a permanent loss is the job; upside takes care of itself.
11 more questions on Case study, with model answers, inside.
19 questions in this topic
Ownership of outcomes over a multi-year hold rather than transaction-by-transaction; the investor mindset (is this a good business at this price?) vs execution; working with management to build value; and concentrated, high-conviction work. Ground it in specific deals or sectors you find interesting.
PE combines the deal execution of banking with an owner's mindset and multi-year value creation: you buy, improve and sell real businesses, not just advise or trade. Versus a hedge fund, it's concentrated, control-oriented and operational rather than a liquid market view. Ground it in specific deals or sectors and the type of work you want.
Pick something you genuinely follow: state the business, why it's a good business, the price/valuation and why it's attractive now, the 2-3 things that have to go right, the key risk, and your expected return. It tests whether you think like an investor: a view, a valuation, and an honest risk: not whether you picked a "winner".
16 more questions on Fit, with model answers, inside.
5 questions in this topic
A limited partnership: the GP (the PE firm) manages, LPs (pensions, endowments, insurers, sovereign wealth) provide most of the capital. Typical terms: ~10-year life, a ~5-year investment period, ~2% management fee and ~20% carried interest above a ~8% hurdle. Capital is drawn ("called") as deals close and returned as they exit.
Dry powder is committed but not-yet-invested capital. High dry powder means intense competition for deals (bidding up entry multiples, pressuring returns) and pressure to deploy before the investment period ends. It's a key market indicator: record dry powder in 2021-23 kept entry prices high even as financing tightened.
Committed capital is what LPs pledge to the fund; invested (called/drawn) capital is what's actually been requested and deployed into deals over time. A capital call is the GP requesting a slice of the commitment when a deal closes. LPs earn returns on invested capital and pay fees on commitments: the timing gap is part of the J-curve.
2 more questions on Fund, with model answers, inside.
5 questions in this topic
Intermediaries (bankers running auctions), proprietary outreach to founders/families in target sectors, existing portfolio (add-ons and management relationships), and thematic origination (build a thesis in a subsector, then find targets). Proprietary, off-market deals avoid auction competition and win better prices: sourcing edge is a real competitive advantage.
No auction competition means a lower entry price and more time for real diligence and relationship-building with management: versus a banker-run auction that maximises the seller's price. A sourcing edge (sector relationships, thematic origination) lets a fund buy well, which is the single biggest return driver. It's why firms invest heavily in origination.
Start from the investment thesis, not a list. Define what good looks like (size, margin, recurring revenue, owner situation), then build the universe from trade bodies, industry directories, company filings and conference attendee lists. Screen it down, then prioritise by who is actually likely to sell: founder-owned businesses with a succession question, corporate carve-outs of non-core divisions, and sponsors approaching the end of a fund life. The judgement is in the prioritisation, because the universe is always bigger than the team can call.
2 more questions on Sourcing, with model answers, inside.
19 questions in this topic
Commercial (market, competition, customers, growth), financial/quality-of-earnings (scrub EBITDA, working capital, one-offs), operational (management, systems, scalability), legal (contracts, litigation, IP), tax and structuring, and increasingly ESG and IT/cyber. Each tests a leg of the thesis; the output is a validated investment case and a risk-adjusted price.
A deep scrub of reported EBITDA to find the true, sustainable, recurring earnings: it normalises for one-offs, non-recurring items, accounting choices, owner add-backs and run-rate adjustments, and tests working-capital and revenue quality. Since price = multiple × EBITDA, every dollar of overstated EBITDA is a multiple of overpayment: QoE protects the buyer.
Reject the add-back, if it recurs, it's operating, so real EBITDA is $5m lower, cutting the value by $5m × the multiple (e.g. $50m at 10x) and the debt the business can carry. I'd re-cut the model on the corrected number, revisit the price, and flag it as a seller-aggressive adjustment that colours how I read the rest of their add-backs.
16 more questions on Diligence, with model answers, inside.
16 questions in this topic
Revenue (pricing, sales-force effectiveness, new products/geographies, cross-sell, churn), margin (procurement, cost-out, operating leverage, footprint), capital efficiency (working capital, capex discipline), and M&A (accretive add-ons). Plus better management, incentives and reporting. Modern PE underwrites operational improvement: quantify each lever's EBITDA impact and its cost/time to deliver.
Diagnose first: benchmark gross and operating margin vs peers to find the gap. Then pull levers: pricing/discount discipline, procurement and supplier renegotiation, footprint/overhead rationalisation, mix shift to higher-margin products, automation, and shared services. Prioritise by size and speed, sequence them, and make sure cuts don't damage growth or quality.
The prioritised action list for the first ~100 days post-close: quick wins, key hires, aligning management incentives, setting up reporting/KPIs, and kicking off the big value-creation initiatives. It sets the pace and signals ownership from day one. Momentum early: especially cash and pricing quick wins: de-risks the hold.
13 more questions on Value creation, with model answers, inside.
11 questions in this topic
Growth equity takes minority stakes in fast-growing, often profitable-ish companies with little or no leverage, betting on continued growth rather than financial engineering and control. Returns come from revenue growth and multiple, not deleveraging. It sits between VC (early, high-risk) and buyouts (mature, levered, control) on the risk/control spectrum.
Growth equity typically takes a minority stake with little or no leverage, investing primarily to fund expansion, sales, product, geography, in a company that's already proven its model, versus a buyout taking control with significant debt to acquire a mature, cash-generative business. Growth investors underwrite mostly on revenue growth and market expansion, not leverage-driven returns.
The target companies are often still investing heavily in growth, not yet generating the stable, predictable cash flow a lender needs to underwrite debt service, so returns come almost entirely from revenue and enterprise value growth, aligning with the founder, rather than from a leveraged capital structure or multiple arbitrage.
8 more questions on Growth equity, with model answers, inside.
5 questions in this topic
Buying existing LP fund interests (or a GP-led restructuring of a portfolio into a continuation vehicle) rather than investing in new companies. It offers liquidity to sellers, a shorter J-curve and visibility into the underlying assets for buyers. GP-led secondaries (continuation funds) have boomed as an alternative exit route when IPO/M&A windows are shut.
The GP sets up a new fund vehicle to buy one or more assets out of an existing, often end-of-life, fund, giving LPs the choice to cash out at the negotiated price or roll into the new vehicle for continued exposure. They've grown because they let a GP hold a high-conviction asset longer than the original fund's life allows without a forced sale, while still giving existing LPs liquidity.
An LP sells its existing fund stake, or a portfolio of stakes, to another investor, often a dedicated secondaries fund, before the underlying fund has fully realized. It's how LPs manage liquidity needs, rebalance exposure, or exit a relationship, without waiting for the GP to exit every underlying company.
2 more questions on Secondaries, with model answers, inside.
11 questions in this topic
Non-bank lenders (direct lending funds) providing loans directly to mid-market and PE-backed companies: often unitranche, floating-rate, held to maturity. It's grown because banks retreated from leveraged lending after 2008 regulation, sponsors value speed/certainty/flexibility, and higher base rates made floating-rate private loans attractive to yield-hungry LPs. It now rivals the syndicated loan market.
Direct lending is a private credit fund originating and holding a loan directly with a borrower, often a PE-backed company, negotiated bilaterally or with a small club of lenders, versus a syndicated loan underwritten by a bank and sold down to many institutional investors in the broadly syndicated market. Direct lending is typically faster to close and more flexible on terms, but usually priced higher to compensate for illiquidity and concentration.
A single blended debt tranche that combines what would otherwise be separate senior and subordinated or mezzanine debt into one loan with one lender, or small club, and one set of terms, at a blended interest rate between senior and mezz pricing. It simplifies the capital structure and negotiation for the borrower versus stacking multiple tranches with different lenders.
8 more questions on Private credit, with model answers, inside.
11 questions in this topic
Public multiples de-rated (especially tech) while business quality held, leaving quality companies cheap and easier to transform away from quarterly scrutiny. Evaluate: is there a real value-creation runway, can cash flows support a control premium plus leverage, is the founder/board aligned, and is there a credible re-exit? Premium paid vs improvement potential is the crux.
A period after signing a deal, often 30 to 45 days, during which the target can actively solicit competing offers even though it's already agreed to a deal, with a lower break fee if a better offer emerges during that window than after it closes. Boards use it to demonstrate they ran a fair process and got the best price, protecting against shareholder litigation that the deal was under-shopped.
Public company merger agreements typically don't include a financing-out condition, unlike some private deals, so target boards and shareholders need very high confidence the buyer can actually fund the deal. Hence the emphasis on committed debt financing letters and equity commitment letters from day one, not just a term sheet.
8 more questions on Take-private, with model answers, inside.
6 questions in this topic
Trade sale (to a strategic: often the highest price via synergies), secondary buyout (to another sponsor), IPO (partial exit, market-dependent, retains upside), dividend recap (partial, keeps the asset), or a GP-led continuation fund. The choice depends on market windows, buyer appetite, the asset's scale/story, and the fund's need for liquidity/DPI. You plan the exit at entry.
IPO when the company is large and high-quality enough to be a compelling public story, public multiples are attractive, and you want to retain upside via a staged exit (sell down over lock-ups). Sell (trade/secondary) when a buyer will pay a full price now with certainty, the equity story suits private ownership, or public markets are shut. Certainty and price versus retained upside is the trade.
Speed and confidentiality, avoiding signaling to employees, customers, or competitors that the company is for sale, lower deal costs, and sometimes a specific buyer, often a strategic already familiar with the asset, willing to pay a full price without needing the competitive tension of an auction to get there.
3 more questions on Exit, with model answers, inside.
7 questions in this topic
Recurring revenue, high gross margins, strong retention and pricing power, low capital intensity, and fragmentation for buy-and-build: all supporting leverage and reliable compounding. Sticky, mission-critical software with high switching costs is prized. The risk is entry multiples got very high, so returns now hinge on genuine growth and operational value-add, not multiple expansion.
Attractive: demographic tailwinds, fragmentation (roll-ups), recurring demand, and non-discretionary spend. Tricky: reimbursement and regulatory risk (a policy change can reset economics), labour shortages, and reputational/clinical risk. The thesis must survive a reimbursement cut, and roll-ups need genuine integration, not just multiple arbitrage on a regulated revenue base.
Opportunities: renewables, grid/EV infrastructure, energy efficiency, and decarbonisation services: long-duration, often contracted cash flows suiting infra-style capital. Risks: policy/subsidy dependence, technology and commodity-price risk, and long payback. It's a huge capital-deployment theme, but returns depend on regulatory durability and disciplined entry into a crowded, capital-hungry space.
4 more questions on Sector, with model answers, inside.
17 questions in this topic
As both risk and value: material ESG risks (regulatory, environmental liabilities, governance, reputational) can impair value or the exit, while ESG improvements (energy efficiency, better governance, diversity, safety) can cut costs, widen the buyer pool and lift the exit multiple. Serious firms diligence material ESG factors and build them into the value-creation plan, not as box-ticking but as value and risk drivers.
Yes: a cleaner ESG profile widens the universe of buyers (many strategics and LPs have mandates), reduces perceived risk, and can evidence operational quality (safety, governance, efficiency), all of which support a higher multiple and smoother sale. It has to be substantive and measurable, tied to cash flows or buyer demand, not greenwashing, but it's increasingly a real value lever.
It's folded into commercial and legal diligence, not a separate box-check: environmental liability review, contamination, permits, regulatory compliance, by specialist consultants for industrial targets, governance review of the cap table and board structure, and increasingly a materiality assessment of which E, S, or G factors could actually move enterprise value or create liability.
14 more questions on ESG, with model answers, inside.
5 questions in this topic
A co-investment lets an LP invest directly alongside the GP in a specific deal, usually with reduced or no fees and carry. LPs want it to lower blended costs, concentrate in deals they like, and deepen the GP relationship. GPs offer it to close larger deals without over-concentrating the fund and to reward key LPs. The catch for LPs: less diversification and adverse selection risk.
The LP is taking single-deal, undiversified risk without the GP doing new sourcing work specifically for them, they're riding along on a deal the fund is already doing. Reduced economics reflect that the GP's marginal work and risk-bearing for the co-invest slice is lower than for a full fund commitment.
The concern that a GP might preferentially offer co-invest capacity on its riskier or larger deals, where it wants to share exposure, rather than its highest-conviction deals, so an LP's co-invest book could be systematically lower quality than the fund's overall portfolio. Sophisticated LPs track co-invest performance separately against the main fund to check for this.
2 more questions on Co-invest, with model answers, inside.
5 questions in this topic
Track record (net returns by vintage, DPI not just TVPI, loss ratios), team stability and succession, strategy consistency and discipline, the sourcing edge, value-creation capability (not just financial engineering), alignment (GP commitment, terms), and how they performed through a downturn. You're backing a repeatable process and a stable, aligned team: not a lucky fund or a hot deal.
Track record decomposed by deal, how much return came from leverage or multiple expansion versus real operational value creation, team stability and succession plan, strategy consistency between the new fund and the one the track record was built on, and references from other LPs and portfolio company management, not just headline IRR and MOIC.
A subset of LPs, often the largest commitments, that the GP consults on conflicts of interest, valuation disputes, and certain LPA amendments or waivers. It's not a governance board with control over investment decisions, it's narrowly scoped to specific consent rights defined in the LPA, mainly around conflicts.
2 more questions on LP, with model answers, inside.
7 questions in this topic
A pool of equity/options (often ~10-15%) for the leadership team that vests on returns: typically a ratchet where management's share of the upside rises as the sponsor clears MOIC/IRR hurdles. It aligns them with the sponsor (they win big only if the equity does) and is a key retention tool. Structuring the hurdles and vesting to motivate without over-diluting is an art.
To bridge a valuation or funding gap with a return-accruing, downside-protected layer: preferred equity gets a fixed return and priority over common before the sponsor/management share upside; PIK notes accrue non-cash interest to preserve near-term cash. They add leverage-like return without cash servicing pressure: useful, but they compound and can crowd out common equity if the deal underperforms.
To bridge a valuation gap or share risk: an earnout ties part of the price to future performance (aligning an optimistic seller), while a seller note has the seller finance part of the purchase (deferred, subordinated), reducing the buyer's upfront funding and signalling the seller's confidence. Both defer/condition consideration; the trade-offs are measurement disputes (earnout) and the seller's credit exposure (note).
4 more questions on Structuring, with model answers, inside.
4 questions in this topic
Overpaying at entry: a high multiple that leaves no room for error, so any EBITDA miss or multiple compression wipes the levered equity. Runners-up: too much leverage into a downturn, a broken thesis (structural decline underestimated), and weak management. Entry price and prudent leverage protect against the downside; expensive, over-levered deals are fragile to any bad news.
Floating rate debt reprices, so interest cost rises without any deterioration in the business, compressing the interest coverage ratio and the cash available to repay principal. Refinancing risk bites at maturity if spreads have widened. Exit multiples typically compress as rates rise, since the discount rate on every buyer's model is higher. The three compound: you pay more to hold the asset and get less when you sell it.
In rough order of cost: cure it with an equity injection from the sponsor, ask lenders for a waiver or amendment (usually for a fee and a higher margin), reset the covenant in exchange for tighter terms elsewhere, or restructure the balance sheet. The sponsor's decision turns on whether this is a timing problem or a value problem: injecting equity into a business that is permanently impaired is good money after bad, and lenders will read the sponsor's willingness to support as a signal either way.
1 more question on Risk, with model answers, inside.
8 questions in this topic
Buying a company's debt, often at a discount, with the intent of converting that debt into equity control through a bankruptcy restructuring or out-of-court exchange, effectively acquiring the business via the liability side of the balance sheet rather than a traditional equity purchase. It's a way to gain control of a distressed asset at a lower effective basis than an equity buyout.
Creditors agree to exchange some or all of their debt claims for equity in the reorganized company, reducing the company's debt burden and cash interest cost in exchange for creditors taking on equity risk and upside instead of a fixed claim. It's a core mechanism of most Chapter 11 reorganizations and out-of-court restructurings.
A sale of assets under section 363 of the US Bankruptcy Code, done free and clear of most existing liens and liabilities, approved by the bankruptcy court, often via an auction process. It's attractive because the buyer gets the operating assets without inheriting the seller's legacy liabilities or having to negotiate with every creditor individually.
5 more questions on Turnaround, with model answers, inside.
4 questions in this topic
Most leveraged loans are floating rate, so a rise in base rates directly increases cash interest expense without any change in the business itself, which can compress free cash flow available for debt paydown or even threaten covenant compliance. Sponsors increasingly use interest rate hedges, caps or swaps, on a portion of the debt stack specifically to manage this exposure, especially on deals underwritten with limited cash flow cushion.
The risk that when existing debt matures, the company can't refinance on acceptable terms, or at all, due to a weaker credit market, deteriorated company performance, or a maturity wall coinciding with market stress. Sponsors manage it partly by negotiating longer initial maturities with cushion past the expected hold period, and by avoiding stacking too much debt to mature in a single year across the portfolio.
It depends on the stability and the cash conversion of the earnings, not on the sector label. The test is coverage: can EBITDA less capex comfortably service interest with room for a bad year? Stable, contracted, asset-light businesses with high cash conversion support more; cyclical, capex-heavy or customer-concentrated ones support less. Quoting a turns number without naming the cash flow test is the wrong answer even when the number is right.
1 more question on Leveraged, with model answers, inside.